Phase 1 Trial of a Therapeutic Anti-Yellow Fever Virus Human Antibody.
Jenny G LowJustin H J NgEugenia Z OngShirin KalimuddinLimin WijayaYvonne F Z ChanDorothy H L NgHwee-Cheng TanAnjali BaglodyYok-Hian ChionhDebbie C P LeeYadunanda BudigiRam SasisekharanEng-Eong OoiPublished in: The New England journal of medicine (2020)
This phase 1 trial of TY014 did not identify worrisome safety signals and suggested potential clinical benefit, which requires further assessment in a phase 2 trial. (Funded by Tysana; ClinicalTrials.gov number, NCT03776786.).